Ipsen announced that the results of the ELECT(R) phase III clinical study with Somatuline(R) Autogel(R) /Somatuline(R) Depot(R) (lanreotide) Injection (hereafter referred to as Somatuline(R)) will be presented on Friday 17 January 2014 at the Gastrointestinal Cancers Symposium, San Francisco, CA, USA. Results of the ELECT(R) phase III study (poster 268) showed that treatment with Somatuline(R) 120 mg versus placebo resulted in a statistically significant reduction in the number of days in which immediate release octreotide was used as rescue medication, representing a mean difference of -14.8%. Somatuline(R) significantly improved the rates of complete/partial treatment success versus placebo.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
111.2 EUR | +0.36% | +1.83% | +3.06% |
11/07 | CAC40: maintains gains after reassuring US inflation figures | CF |
11/07 | CAC40: rise without volume, W-Street at its zenith but falls back | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.06% | 1TCr | |
+55.35% | 82TCr | |
+31.64% | 60TCr | |
-0.10% | 38TCr | |
+15.47% | 32TCr | |
+13.10% | 31TCr | |
+15.51% | 25TCr | |
+16.72% | 23TCr | |
+16.54% | 18TCr | |
+4.31% | 17TCr |
- Stock Market
- Equities
- IPN Stock
- News Ipsen
- Ipsen Announces Results of the ELECT(R) Phase III Clinical Study with Somatuline(R) Autogel(R) /Somatuline(R) Depot(R) Injection